More Than 80 Countries Convene Virtually to Learn How U.S. Soy is Ready to Deliver
This week the U.S. Soybean Export Council (USSEC) hosted more than 1,600 global customers and soybean industry representatives from 84 countries. The two-day global digital event, The U.S. Soy Connection: Global Digital Conference and Situation Report, highlighted to international customers the strength of U.S. soybean farmers and the soybean value chain. In providing nutrition and information to customers of U.S. Soy at this critical time, U.S. Soy remains open for business despite uncertainty due to the novel COVID-19 virus.
“The value of our partnerships is immeasurable, not only for soy, but for the world at large. Our collaboration across U.S. agriculture will help provide the global market with a stable supply of high-quality products and support,” said Monte Peterson, Chairman of USSEC, board member of the American Soybean Association and soybean farmer in Valley City, N.D. “By hosting events like this, we can address our partners' concerns and learn directly about their challenges. And as we move ahead into the 2020 planting season and beyond, U.S. soybean farmers are committed to provide a sustainable crop and serve as a consistent supplier to our customers.”
Sessions were held over two days and noteworthy speakers included Thomas Mielke, Executive Director of ISTA Mielke Oil World, Emily French, Managing Director at ConsiliAgra, Soren Schroder, Former CEO of Bunge Limited, several USSEC board members and U.S. exporters from across the country.
“Throughout the conference, we showcased that despite the global impact of coronavirus, the supply of U.S. Soy remains unwavering,” said Jim Sutter, USSEC CEO. “During this unique time, our priority is containing the outbreak and ensuring that all members of the soy value chain are safe. USSEC will continue to work tirelessly to show our partners that our entire supply chain is working to ensure a sustainably and safely produced, reliable supply of soy for global customers. It’s imperative that we also provide them with practical information about the global/U.S. market that they rely on from our USSEC events around the world.”
On April 14 attendees heard from globally recognized experts who discussed U.S. soybean trends and the impact that COVID-19 is having on the industry.
Highlights from Day 1:
Thomas Mielke, Executive Director of ISTA Mielke Oil World, discussed COVID-19’s impact on global oilseed supply and demand.
“The Chinese soybean crush has exceeded expectations in the first half of this crop year 2019/20 and domestic soybean meal demand has actually started to increase from a year ago. In China, imports of soybeans are recovering. They increased significantly by approximately eight million tons from a year ago to 37.4 million tons in Oct./Feb. 2019/20, of which 12.8 million tons of U.S. soybeans against the unusually low quantity of only one million tons a year earlier. We expect China to resume purchases of U.S soybeans in the coming weeks while Brazil exports (after record shipments in March and April) will start declining from May onward. Total Chinese soybean imports are set to recover to 91 million tons in Oct./Sept. 2019/20, of which include 21 million tons from the U.S. and 58 million tons from Brazil.”
Emily French, Managing Director at ConsiliAgra, reported on the impact of several severe black swan events and their effect on the global soy complex.
“There's no question that it's agriculture that makes the world go around. Global agriculture continues to do what it does best, and that is feed and nurture the world. As we move through COVID-19, the value of free and reciprocal trade has never been more evident.”
On April 15, industry leaders and U.S. soybean farmers reported on their plans for 2020 planting. In addition, several U.S. exporters hosted a panel discussion to give an update on logistics and export demand.
Highlights from Day 2:
Soren Schroder, Former CEO of Bunge Limited, presented on the reliability and innovation of U.S agriculture.
“Disruptions can take many forms for crops such as the global crisis that we're experiencing now. The U.S. capacity runs on all coasts with highly efficient multi-modal interior logistic systems which ensure a continuous supply; this makes the U.S. export infrastructure very flexible. Both interior and export terminals are highly automated making them more resilient. In short, the U.S. supply chain can be relied upon like no other.”
Doug Winter, U.S. Soybean Export Council Vice Chairman and United Soybean Board Director; U.S. soybean farmer from Illinois
“U.S. Soy benefits buyers around the world by making more of an effective effort toward satisfying the needs of our international customers. The communication around marketing, the quality of crop and learning the needs of our buyers all work together to help us as farmers support our customers and make better decisions. Whether meeting in person or virtually, it helps us align on a common goal to increase the effectiveness and efficiency of soy.”
Joel Schreurs, Director, U.S. Soybean Export Council and American Soybean Association; U.S. soybean farmer from Minnesota
“Technology makes us considerably more efficient. Every two-and-a-half-acre parcel of land on our farm has a different prescription as far as what fertilizer is needed and what the crop itself will utilize. We maintain records each year to learn how to be better stewards of the land, which benefits the environment and enhances our yields for the future.”
In order to allow participants from multiple time zones to participate in this event, the presentations were repeated twice within each 24-hour period. Click here to learn more and/or request a recording of the conference.
ABOUT U.S. SOYBEAN EXPORT COUNCIL
The U.S. Soybean Export Council (USSEC) is a dynamic partnership of U.S. soybean producers, processors, commodity shippers, merchandisers, allied agribusinesses, and agricultural organizations working to build preference for U.S. Soy throughout the world. Through a global network of international offices and strong support in the U.S., USSEC works to build a preference for U.S. soybeans and soybean products, advocates for the use of soy in feed, aquaculture and human consumption, promotes the benefits of soy use through education, and connects industry leaders through a robust membership program. USSEC is partially funded by the United Soybean Board. Learn more at www.ussec.org.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 20:31:00 CEST | Press release
Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu
Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig ® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 14:00:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r
Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO ® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 14:00:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo
Takeda to Present Data from the ICLUSIG ® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 14:00:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the 25thEuropean Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR-A
Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS29.5.2020 14:00:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56thAmerican Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25thEuropean Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone. The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, higher-risk chronic myelomonocytic leukemi
LetsGetChecked Debuts FDA EUA-Authorized At-Home Coronavirus (COVID-19) Sure-track Test29.5.2020 13:57:00 CEST | Press release
LetsGetChecked, the leading direct-to-consumer at-home health testing and insights company, announces today the authorization of the new Coronavirus (COVID-19) Sure-track Test for at-home consumer use by the U.S. Food and Drug Administration under an EUA. The new test is authorized to serve at-risk individuals with a proprietary at-home PCR nasal swab test that delivers accurate and definitive results within 24 hours. Offering an end-to-end model, LetsGetChecked’s new Sure-track Test introduces the most complete FDA EUA-authorized Coronavirus at-home testing solution. The at-home Coronavirus (COVID-19) test incorporates a nasal swab and PCR lab analysis, offering convenient and secure results in 24 hours. Unlike serology tests that detect the presence of antibodies, the at-home COVID-19 test determines the presence or absence of SARS-CoV-2 viral RNA. LetsGetChecked’s Sure-track Test is the only FDA EUA-authorized at-home Coronavirus (COVID-19) test that owns all aspects of the testing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom